AzurRx (AZRX) Corporate Media Kit

33 Interim Data from the First Five Patients in Combination Study Primary and Secondary Efficacy Endpoints Met, No Safety Issues V2 V4 V5 V6 PERT (Baseline) + 700mg/day MS1819 + 1120mg/day MS1819 + 2240mg/day MS1819 CFA (%) 78.4 88.4 87.2 86.5 CNA (%) 96.6 97.7 98.0* 97.4* Stool Weight (g/72h) 784.2 566.6 565.0 526.6 Steatorrhea (g/24h) 21.0 11.5 12.7 13.6 # Stools per day 6.8 4.8 4.8 4.8 Body Weight (Kg) 47.6 48.6 48.6 49.4 Mean Values * CNA data not available for one patient on V5 and one patient on V6.